Health Canada Investigates Gilenya
Health Canada has announced that it will investigate the multiple sclerosis drug Gilenya (fingolimod) after learning of serious adverse events it can cause, including death.
There have been 11 deaths reported internationally so far that have been linked to Gilenya use, three of which involved heart attacks. One of the incidences involved a disturbance of the heart’s rhythm while the other seven remained unexplained, Health Canada reported. One of the patients whose death was unexplained died within 24 hours of taking a dose of Gilenya.
There have been no deaths reported in Canada.
This investigation comes approximately one month after health regulators from the U.S. and Europe decided to review the drug.
If you or a loved one has been harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to find out if you have grounds to pursue legal action.